The Application of P300-Long-Latency Auditory-Evoked Potential in Parkinson Disease

Natalia Ferrazoli1,2, Caroline Donadon2,3, Adriano Rezende2, Piotr H. Skarzynski4,5, Milaine Dominici Sanfins2,6

1 Postgraduate Program in Health, Interdisciplinary Practice and Rehabilitation, Universidade Estadual de Campinas, Campinas, SP, Brazil
2 Clinica Ouvire, Campinas, SP, Brazil
3 Postgraduate Program in Child and Adolescent Health, Universidade Estadual de Campinas, Campinas, SP, Brazil
4 Department of Teleaudiology and Hearing Screening, World Hearing Center, Institute of Physiology and Pathology of Hearing, Warsaw/Kajetany, Poland
5 Department of Heart Failure and Cardiac Rehabilitation, Institute of Sensory Organs, Warsaw, Poland
6 Centro de Eletrofisiologia e Neuroaudiologia Avançada, Sao Paulo, SP, Brazil

Address for correspondence Caroline Donadon, Rua Goncalves Cesar 146, Jardim Guanabara, Campinas, Sao Paulo, Brazil (e-mail: caroldonadon.fono@gmail.com; carol_donadon@hotmail.com).

Abstract

Introduction Parkinson disease (PD) is a degenerative and progressive neurological disorder characterized by resting tremor, stiffness, bradykinesia, and postural instability. Despite the motor symptoms, PD patients also consistently show cognitive impairment or executive dysfunction. The auditory event-related potential P300 has been described as the best indicator of mental function, being highly dependent on cognitive skills, including attention and discrimination.

Objective To review the literature on the application and findings of P300 as an indicator of PD.

Data Analysis The samples ranged from 7 to 166 individuals. Young adult and elderly male patients composed most study samples. The Mini-Mental State Examination test, the Unified Parkinson Disease Rating Scale, and the Hoehn and Yahr Scale were used to assess neurological and cognitive function. In terms of testing hearing function, few studies have focused on parameters other than the P300. The factors we focused on were how the P300 was modified by cognitive effects, its correlation with different PD scales, the effect of performing dual tasks, the effect of fatigue, and the influence of drug treatments.

Conclusion The use of the P300 appears to be an effective assessment tool in patients with PD. This event-related potential seems to correlate well with other neurocognitive tests that measure key features of the disease.

Keywords

► Parkinson disease
► attention
► P300
► event-related potential
► elderly

ISSN 1809-9777.

© 2021. Fundação Otorrinolaringologia. All rights reserved.
This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda., Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
Introduction

Parkinson disease (PD) is a degenerative and progressive neurological disorder characterized by resting tremor, stiffness, bradykinesia, and postural instability. Despite being commonly associated with motor disorders, PD patients often show cognitive impairment or executive dysfunction, with difficulty starting tasks, lack of cognitive flexibility, dementia, lack of attention, and difficulty adapting to new stimuli.

The event-related potential (ERP) component known as the P300 is a neurophysiological parameter that has been found to correlate with cognitive processes, arising when an individual consciously recognizes a change in an auditory stimulus, a novel stimuli. The P300 potential identifies the positive component wave, with a peak around 300 ms, which is generated after a novel sound stimulus.

By measuring an increase in latency, or sometimes a decrease in the amplitude of the P300 wave, it is possible to monitor the loss of cognitive functions associated with the processing of sound information. The measurement of such cognitive abilities as attention, discrimination, integration, memory, and decision-making can be performed.

In view of the clinical use of the P300 potential to assess the cognitive skills in patients with degenerative and neurological disorders, the P300 has been proposed as a candidate biomarker for the progression of PD. The P300 is appreciably smaller in severe cases. The aim of the present study was to examine the use of P300 measurements in patients with PD and to identify consistent outcomes.

Fig. 1 Flowchart of the selection of the studies.
<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>Sample</th>
<th>Complementary assessment</th>
<th>Results</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cavanagh et al.</td>
<td>2018</td>
<td>SG: 25 individuals with PD (age: 69.69 ± 8.73 years; 16 M). DD: 5,46 ± 4.09. CG: 25 healthy controls (age: 69.32 ± 9.58 years; 16 M).</td>
<td>MMSE, NAART, BDI, UPDRS.</td>
<td>The P300 component trended toward being larger in the PD group than in the CG.</td>
<td>There was an association between PD severity and P300 prolonged latencies among older subjects. This prolongation is more emphasized in individuals in advanced stages of the disease.</td>
</tr>
<tr>
<td>Lei et al.</td>
<td>2019</td>
<td>SG: 23 individuals with PD (age: 61 ± 9 years; 11 M). DD: 7 ± 5 years. CG: 23 healthy controls (age: 61 ± 8 years; 11 M).</td>
<td>CERAD-Plus, NAI stroop test, FAB, BDI, GDS, ERP.</td>
<td>The patients showed larger P300 amplitudes for periodic versus random tones, for sitting, pedaling conditions, and the controls showed a timing effect only for the sitting condition.</td>
<td>A correlation between P300 amplitudes and motor variability in the periodic pedaling condition was only obtained in control participants.</td>
</tr>
<tr>
<td>Silva Lopes et al.</td>
<td>2014</td>
<td>SG: 44 individuals with PD (age: 48–81 years; 24 M). DD: 7 years. CG: 23 healthy controls (age: 61 ± 8 years; 11 M).</td>
<td>MMSE, UPDRS, PTA, ABR.</td>
<td>There was a correlation between latencies and non-motor clinical features. Subjects older than 65, in advanced stages, presented a significant increase in latencies.</td>
<td>There was an association between PD severity and P300 prolonged latencies among older subjects.</td>
</tr>
<tr>
<td>Maidan et al.</td>
<td>2019</td>
<td>SG: 10 individuals with PD (age: 60.5 ± 3.6 years; 6 M). DD: 2.9 ± 0.5 years. CG: 11 healthy young adults (age: 32 ± 18 years; 7 M). CGII: 10 healthy older adults (age: 67.1 ± 1.7 years; 4 M).</td>
<td>MoCA, CTT, UPDRS.</td>
<td>Prolonged P300 latency during walking is more pronounced in aging and PD. There is an association between P300 latency and reduced cognitive function. Reduced P300 amplitude was found only in patients with PD.</td>
<td>The physiological recruitment of attentional networks during walking and their impact by aging and disease.</td>
</tr>
<tr>
<td>Naskar et al.</td>
<td>2010</td>
<td>SG: 10 individuals with idiopathic PD (age: 52.5 ± 5.17 years; 6 M). DD: 9.5 ± 2.4 years.</td>
<td>HY, hearing test and MMSE.</td>
<td>DBS may also worsen the orientation response as reflected by the increase in the N100 latency after the DBS electrode is turned on.</td>
<td>Neither amplitudes nor areas of the ERP components changed significantly. There was no significant change in the latency of the P300 potential when the target stimulus was applied.</td>
</tr>
<tr>
<td>Authors</td>
<td>Year</td>
<td>Sample</td>
<td>Complementary assessment</td>
<td>Results</td>
<td>Conclusion</td>
</tr>
<tr>
<td>------------------</td>
<td>------</td>
<td>------------------------------------------------------------------------</td>
<td>----------------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>6 Pauletti et al.</td>
<td>2019</td>
<td>SC I: 11 individuals with PDF (age: 68.3 ± 9.8 years; 9 M). DD: 5.6 ± 4.5 years. SC II: 24 individuals with PDnF (age: 65.2 ± 6.8 years; 18 M). DD: 3.8 ± 2.8 years. CG: 32 healthy controls (age: 62.8 ± 9.3 years; 20 M). MMSE, HY, UPDRS, PDQ-39, PSQI, STAI, BDI.</td>
<td>P300 latency was significantly longer in the PDF and PDnF groups than in the controls. P3a latency and P3a amplitude were respectively significantly longer and lower in the PDF group than in either the PDnF group or the controls.</td>
<td>PDF patients exhibited a difficulty in attentional orienting to salient novel stimuli.</td>
<td></td>
</tr>
<tr>
<td>7 Sarikaya et al.</td>
<td>2014</td>
<td>SG: 38 individuals with PD (age: 58.8 years; 25 M). CG: 39 healthy patients (age: 63.5 years; 25 M). SMMT, UPDRS, HY, HAM-D.</td>
<td>P300 latencies in PD patients were significantly prolonged compared with the control group. There was a decrease in P300 amplitude values with increasing HAM-D.</td>
<td>P300 latency reflects the rate of stimuli classification by mental process, attention, and cognitive processing. There is a dysfunction in these functions, and it can be demonstrated by the P300 test.</td>
<td></td>
</tr>
<tr>
<td>8 Solís-Vivanco et al.</td>
<td>2015</td>
<td>SCI: 28 individuals with PD at stage 1 of the HY (age: 56.2 ± 8.8 years; 16 M). DD 3.0 ± 2.1 years. SCII: 14 individuals with PD at stage 2 of the HY (age: 57.2 ± 8.5 years; 12 M). DD 5.3 ± 3.9 years. SCIII: 13 subjects diagnosed with PD at stage 3 of the HY (age: 64.9 ± 8.3 years; 5 M). DD 10.0 ± 4.8 years. CG: 24 healthy subjects (age: 51.6 ± 7.8 years, 12 M). HY, BDI, MMSE, MMN, RON.</td>
<td>The P300 amplitude was significantly lower in all PD groups compared with the control group, especially for stages 2 and 3. The disease duration inversely predicted the P300.</td>
<td>The P300 could be a potential, well suited cognitive biomarker of progression in mild-to-moderate PD.</td>
<td></td>
</tr>
<tr>
<td>9 Solís-Vivanco et al.</td>
<td>2011</td>
<td>SC I: 25 medicated individuals with PD (age: 55.1 ± 7.6 years; 15 M). DD: 4.9 ± 3.1 years. SC II: 17 non-medicated individuals PD (age: 56.9 ± 7.2 years; 13 M). DD: 2.4 ± 2.2 years. CG: 20 healthy controls (age: 51.7 ± 7.6 years; 10 M). MMSE, BDI, HY.</td>
<td>A significant lower P300 amplitude in the medicated group compared with the control group.</td>
<td>There were no significant differences in the latencies of any of the waves among the groups. The main finding of this study was the reduction in the IA in early PD.</td>
<td></td>
</tr>
<tr>
<td>Authors</td>
<td>Year</td>
<td>Sample</td>
<td>Complementary assessment</td>
<td>Results</td>
<td>Conclusion</td>
</tr>
<tr>
<td>------------------</td>
<td>------</td>
<td>------------------------------------------------------------------------</td>
<td>--------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Tang et al.</td>
<td>2016</td>
<td>SGI: 76 EOPD (age: ≤ 50 years). DD: 11.96 ± 7.12 years. SG II: 166 LOPD (age: &gt; 50 years). DD: 3.63 ± 4.29 years.</td>
<td>UPDRS, HY, MMSE, MoCA, WAIS-RC, WMS-RC.</td>
<td>P300 latencies were markedly delayed, and P300 amplitudes were reduced, in the LOPD group. In addition, the amplitudes of P3 at Cz and Pz in the LOPD group were significantly reduced compared with those observed in the EOPD group.</td>
<td>Cognitive dysfunction progressed more slowly in the EOPD group. Although the LOPD patients exhibited shorter disease durations, their cognitive abilities, including executive function, visuospatial function and attention, may have been impaired.</td>
</tr>
<tr>
<td>Tokic et al.</td>
<td>2016</td>
<td>SC: 21 individuals with PD (age: 70.38 years; 12 M).</td>
<td>—</td>
<td>Patients with PD have prolonged P300 targeted and frequent stimulus latency compared with reference value for healthy population.</td>
<td>The p300 findings in PD patients indicate the presence of cognitive dysfunction in these patients.</td>
</tr>
<tr>
<td>Yilmaz et al.</td>
<td>2017</td>
<td>SG 1: 20 individuals with PD and MCI (age: 61.3 ± 7.8 years; 11 M). DD: 4.0 years. SC 2: 21 individuals with PD without cognitive impairment (age: 60.6 ± 7.8 years; 13 M). DD: 3.0. CG: 20 healthy subjects (age: 59.3 ± 5.7 years; 11 M).</td>
<td>WMS, OVMPT, DST, JOT, BFRT, VFT, CDT, BNT, GAT-2, audiometric threshold of 1,000Hz.</td>
<td>P300 latencies were significantly longer in the PD-MCI group than in the PD-Normal and the control group. The P300 amplitude recorded from the Fz was significantly lower in PD-MCI group than in the other groups.</td>
<td>P300 provides a diagnostic tool to detect MCI in PD, and the prolongation of the P300 potential could be used as supportive parameters in this diagnosis.</td>
</tr>
</tbody>
</table>

Abbreviations: ABR, auditory brainstem response; BDI, Beck Depression Inventory; BFRT, Benton Facial Recognition Test; BNT, Boston Naming Test; CDT, Clock Drawing Test; CERAD-plus, Consortium to Establish a Registry for Alzheimer’s Disease; CG, Control Group; CTT, Color Trail Test; Cz, Central midline sagittal plane electrode placement site; DBS, deep brain stimulation; DD, disease duration; DST, Digit Span Test; EOPD, early-onset Parkinson’s disease; ERP, evoked response potential; FAB, Frontal Assessment Battery; Fz, Frontal midline sagittal plane electrode placement site; GAT-2, Gülhane Aphasia Test-2; GDS, Geriatric Depression Scale; HAM-D, Hamilton Depression Rating Scale; HY, Hoen and Yahr scale; JOT, Judgment of Line Orientation Test; LOPD, late-onset Parkinson’s disease; M, Male; MCI, mild cognitive impairment; MMN, Mismatch Negativity; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; NAI, Nürnberger-Alters-Inventar; OVMPT, Öktem Verbal Memory Processes Test; PD, Parkinson disease; PDF, Parkinson disease with fatigue; PD-MCI, Parkinson disease with mild cognitive impairment; PDNf, Parkinson disease without fatigue; PDQ-39, Parkinson’s Disease Questionnaire–39-Items; PSQI, Pittsburgh Sleep Quality Index; PTA, pure-tone avrage; Pz, Parietal midline sagittal plane electrode placement site; RAS, rhythmic auditory stimulation; RON, Reorientation Negativity; SG, Study Group; SMMT, Standardized Mini Mental test; STA, State Trait Anxiety Inventory; UPDRS, Unified Parkinson’s Disease Rating Scale; VFT, Verbal Fluency test; WAIS-RC, Wechsler Adult Intelligence Scale–Revised for China; WMS, Wechsler Memory Scale, WMS-RC, Wechsler Memory Scale–Revised in Chinese.
Review of the Literature

Methodology
A systematic review of the literature was performed in March 2020 on three databases (PubMed, Web of Science, and Scopus). We searched for full-length articles and abstracts using the Medical Subject Headings (MeSH) parkinson disease AND p300 OR event related auditory potential OR long latency auditory evoked potential.

The titles and abstracts were evaluated by two independent researchers to check if they fitted the inclusion and exclusion criteria. The searches included studies published in the past 10 years (2010–20) which were original articles and tested for auditory P300 using pure-tone stimuli. Animal studies, meeting abstracts, and works in languages other than English were excluded. Disagreements were resolved by discussion and consensus among the authors. Information from the full-text remaining articles was inserted into a Microsoft Excel (Microsoft Corporation, Redmond, WA, US) spreadsheet.

Result
Out of the 360 initial studies (Fig. 1), a total of 12 articles were included in the present review. Information about sample size and characteristics, complementary assessments, P300 findings, and the conclusions from all included articles are summarized in Table 1.

(i) Sample Characteristics
In the 12 articles, most participants were adults or elderly (aged between 32 and 81 years) and male. Yilmaz et al. did not mention the age of their participants. The sizes of the samples ranged from 7 to 166 individuals, in both experimental and controls groups. Four articles used a control group composed of healthy age-matched patients while five used a control group composed of both healthy individuals and those with PD. The study by Tang et al. was composed only of individuals with PD, with different disease durations. Two studies did not include a control group in their methodology. A total of 9 of the articles (75%) considered the time of the disease, while the mean ranged from 2.9 to 9.5 years.

(ii) Neurological and cognitive assessments
Another categorization was the neurological aspect of individuals with PD, factors including executive function, motor function, intelligence quotient (IQ), reasoning, language, memory, and praxis. The most used assessment tool in the studies was the Mini-Mental State Examination (MMSE), appearing in 7 articles followed by the Unified Parkinson’s Disease Rating Scale (UPDRS) and the Hoehn and Yahr (HY) staging scale in 6 articles.

In addition to the P300, other auditory assessments performed by the authors were the Auditory Brainstem Response (ABR), audiometric threshold at 1,000 Hz, auditory air thresholds at 0.5–8 kHz, a hearing test, and self-reported normal auditory function.

(iii) Cognitive ERP (P300) – latency and amplitude effects
The cognitive ERP reflects the time required for auditory processing, and it is frequently studied in patients suffering from PD. In one study, the P300 of subjects with PD had no systematic difference in amplitude; however, it did show a delay (increase in latency) when compared with healthy individuals.

According to the findings of Yilmaz et al., cognitive impairment seemed to affect P300 latency, causing a prolongation in PD patients with mild cognitive impairment (MCI-PD) when compared with DP-Normal and control groups. In that same study, the P300 latency of PD patients with no cognitive impairment was compared with latencies from healthy controls, no difference was found.

Other variables related to PD seem to be associated with changes in the P300 latency and amplitude. Age at the onset of the disease, disease duration, and disease stage seem to have an effect.

When P300 latencies in a group with early onset of PD (at or before the age of 40) were compared with the latencies of a late-onset group (at or after the age of 41), delayed latencies and reduced amplitudes were observed in the late-onset group. These results confirm the negative correlation found between age, P300 latency, and amplitude in PD patients in other studies.

Disease duration can also impact the P300, since the longer the duration of the disease, the lower the amplitude values and the more delayed the latencies. In contrast, another article found no significant differences in PD duration and P300 amplitude and latency.

(iv) PD scales and P300
In one study, the P300 had lower amplitudes in all PD groups compared with the control group, especially for stages 2 and 3 on the HY scale. As for P300 latency, there was one finding of a positive correlation with the severity of PD in individuals aged 65 and older. Notwithstanding, Sarikaya et al. found no significant correlation between HY scale scores and P300 amplitude and latencies.

One study that used the UPDRS scale to measure PD progress found a positive correlation between P300 latency and stage I and II PD patients. Using the same scale, to measure motor and global scores, Sarikaya et al. found no significant difference in the values of P300 latency and amplitude.

(v) Dual tasks and fatigue in P300
Other authors have focused on understanding how the auditory-motor pathway behaves in PD by measuring the P300 during the performance of dual motor tasks and during fatigue conditions. In investigating P300 changes during an odd-ball auditory task between two conditions (that is, standing and walking), the results showed prolonged P300 latency during walking compared with standing in all groups, while P300 amplitude was similar between the two conditions. During the walking task, P300 latency was significantly shorter in the healthy young subjects compared with the healthy older adults and the patients with PD, but no
differences were observed between the healthy older adults and the patients with PD. In the standing task, differences in P300 latency were only observed between healthy young subjects and patients with PD. As for P300 amplitude, smaller values were found while walking compared with standing in patients with PD.

In the cognitive domain, PD patients had larger P300 amplitudes for rhythmic auditory stimulation (RAS) versus random tones for sitting and pedalling conditions. The controls showed an amplitude effect only for the sitting condition, but not for the pedalling condition. However, a correlation between P300 amplitudes and motor variability in the periodic pedalling condition was only obtained in control participants.

Although recent studies have improved our understanding of fatigue, data on the pathophysiological mechanisms underlying this symptom are not yet unequivocal. Central fatigue may be associated with cognitive deficits in PD. P300 latency was significantly longer, and amplitude was lower, in patients with PD and fatigue than in either those with PD but no fatigue, or the controls.

(vi) PD treatments and P300

The P300 has also been used to examine the cognitive effects on the brain in individuals with PD to understand the effects of drug treatments. Solis-Vivanco et al. observed a difference in P300 amplitude in PD patients who were being treated with at least two anti-parkinsonian drugs. There was a lower amplitude in the drug group compared with the healthy control group. When the group with non-medicated PD was compared with the control group, the amplitudes were lower but not statistically significant.

In contrast, another study found statistical differences between the PD and control groups, with greater P300 amplitudes in the PD group (with and without medication) compared with the control group.

In addition to drugs, deep brain stimulation (DBS) surgery and its possible changes in the ERP have been investigated. Naskar et al. investigated recordings of patients with the DBS on and off, and found no statistically significant differences in P300 latencies or amplitudes. However, for the DBS-on condition, P300 latencies became slightly shorter, and the amplitudes also showed a slight decline; however these changes were not statistically significant.

Discussion

Parkinson disease is among the most common neurodegenerative diseases, preceded only by Alzheimer disease. Its signs and symptoms progress over time, so age is clearly a large factor in PD expression. The prevalence of PD is observed mostly in male individuals, and is positively correlated with age, being more prevalent in adults older than 60 years of age, although it can affect adults under the age of 40, corroborating the data collected in the present review.

The diagnosis of PD does not yet have a widely accepted objective measure, which is why it is largely clinical, commonly made by observing indications in the motor and non-motor fields. Diagnostic accuracy can be improved with the use of standardized clinical criteria such as the UPDRS and HY scales.

The scores found on the UPDRS and HY scales correlated positively with the latency values. The UPDRS and HY scores assess losses in mental activity, behavior, mood, and signs and symptoms, factors that allow the individual to be classified in terms of their level of disability, which, in turn, have an effect on generation of the P300.

Researchers presume that the P300 potential might be an important neurophysiological factor associated with cognitive functions such as decision-making, attention, discrimination, integration, and memory skills that are commonly altered in PD patients. This assumption leads us to suppose that the correlations found between scales and latency values might be explained by underlying cognitive, attentional, and executive functions which are involved in the planning and execution of daily-life activities.

However, there are some studies that do not fit the pattern. They fail to verify a relationship between the scales to assess PD and the values of latency and amplitude. Perhaps these anomalies can be explained by the existence of different dopaminergic pathways related to motor and mental impairment in PD, and by the fact that the same score on one scale can originate from different clinical manifestations depending on the individual.

Cognitive decline (dementia) is one of the main changes in upper cortical function that can manifest in 30% to 40% of PD patients. Some degree of cognitive impairment is present at any stage of the disease; for this reason, early cognitive investigation is recommended, as observed in the studies that used MMSE to assess cognitive factors.

As observed by Yilmaz et al., the absence of a statistical difference between P300 latency in a group with PD without cognitive impairment and another group of healthy control individuals can be explained by the hypothesis that frontal executive losses, clearly evident at the beginning of PD, may be more clearly related to altered prefrontal dopaminergic activity, and not necessarily to dementia.

The P300 latency reflects the speed of auditory processing of external stimuli, cognition, and memory capacity, whereas amplitude values define the quality of the auditory information process, as they relate to the number of neurons and attentional resources activated during the task. There is a general consensus that P300 latency increases with age due to the aging of nervous system structures, even in non-pathological individuals; it also increases with a reduction in the cognitive ability to allocate attention and memory resources.

The relationship between the clinical stage of the disease, the duration of the disease, and the age of the patient at its onset can be elucidated by the dopaminergic influence, and the detection of new/rare stimuli has been related to the frontal-striatal functioning suffered by P300. These criteria are related to PD disorders, since, during the initial stage of PD, neurodegeneration is less severe and less extensive than at the most severe moment of the disease, which supports the findings of delayed latency and decreased P300 amplitude observed in PD patients.
Regarding P300 amplitude, some studies\(^6,14\) indicate a decrease in amplitude with increasing age, while others report no clear evidence of the effect of age or disease duration.\(^10\) This variation in findings can be explained by the wide variability in the values found in the analyses. Considering these findings, latency values seem to be more sensitive to small cognitive fluctuations in PD and likely to be influenced by changes in the dopaminergic levels in the brain.

Some theories suggest that motor activities (such as walking or cycling) require higher cognitive processes that use a complex neural network that incorporates cognitive and motor information.\(^29,30\) Studies\(^11,30\) show that the addition of a simultaneous task of executive attention function to the task of walking (motor act) leads to changes in gait performance, and that this effect is exacerbated with aging and neurodegenerative diseases, such as PD.

The prolongation of P300 latency in walking condition in elderly individuals and in those with PD\(^11\) suggests an effect of aging or neurodegeneration, causing the lower processing speed to be accentuated in a more complex task, such as walking. The smaller amplitude only observed in the group with PD when comparing the walking and standing conditions raises the hypothesis that the amount of resources involved during the execution of the double task in PD individuals indicates a lower recruitment of attentional resources and a lower activation of neurons during information processing.\(^31\)

Rhythmic auditory stimulation is defined as a therapeutic application of pulsed rhythmic or musical stimulation to improve gait or aspects related to movement.\(^32\) It has been shown that it can act in the treatment of issues related to the motor domain,\(^33,34\) improving the spatio-temporal characteristics of gait, and cognitive processes, through its temporal predictability\(^33\) in patients with PD.

The findings of Lei et al.\(^8\) indicate that RAS facilitates the processing of predictable events in patients with PD, as well as in healthy individuals, being observed by the increase in the amplitude of responses. The predictability of presenting RAS may have facilitated attentional processing in individuals with PD, since attention can be directed with greater precision at instants close to the appearance of the stimulus.\(^8,33\) However, no correlation was found between P300 amplitudes and motor variability (sitting still or pedalling) in individuals with PD, only in the control group. The accuracy of the sensorimotor synchronization task may be correlated with the functioning of the basal ganglia,\(^35\) the worsening of age-related motor functioning, and a negative effect of added cognitive tasks.\(^36\)

Fatigue is a motor symptom that affects more than 50% of the parkinsonian population,\(^37\) consisting predominantly of central fatigue,\(^38\) which has been linked by researchers to cognitive\(^19,37\) and attention\(^12,18\) deficits in PD. Longer latency and a decrease in amplitude in PD patients compared with controls suggests that they take longer to assess and detect the target stimulus.\(^12\)

However, when comparing parkinsonian patients with fatigue and without fatigue, their latencies were equally prolonged, without statistical significance, which suggests that the fatigue mechanisms and the top-down mechanisms of attentional discrimination of the stimulus are not correlated.\(^12\) This provides indirect evidence of the importance of the connection between cognitive and motor functions during walking.\(^11\) There is an increase in the activation of the prefrontal cortex in young people and healthy elderly people during dual-task walking compared with normal walking.\(^39–41\) Patients with PD showed similar findings, but also showed greater activation during normal walking,\(^42\) suggesting a dependence on cognitive resources even in simple tasks.\(^11\)

For the treatment of PD, dopaminergic agents are generally used to restore the missing neurotransmitter and improve clinical deficits.\(^43\) However, the relationship between the P300, the antiparkinsonian treatment, and PD is still nonspecific. Data indicate either an increase in amplitude\(^7\) or a decrease\(^13\) when individuals undergoing drug treatment are compared with a control group. Authors\(^7,13\) have hypothesized that, in addition to the use of drugs, the stage of the disease may also be a factor to consider. Therefore, the detection of the target stimulus may result in a larger P300 when the disease is more advanced.\(^13\)

Several drugs can treat the symptoms of PD, but, in the long term, the patients will experience the motor complications induced by levodopa.\(^16,44\) Deep brain stimulation has been reported as a procedure that can improve both motor symptoms and cognitive aspects.\(^16,45\) However, the P300 elicited during DBS-on and DBS-off conditions did not show statistically significant changes in latency or amplitude. This finding correlates with the fact that the P300 potential is produced by a series of generators that are not affected by subthalamic nuclei projections.\(^16\)

**Final Comments**

The use of the P300 can be very effective for patients with PD, since this ERP seems to be a good candidate for neurocognitive research in PD. The P300 appears sensitive to the duration and severity of the disease, and it shows marked differences for dual tasks and among the various treatment options applied to PD patients.

**Conflict of Interests**

The authors have no conflict of interests to declare.

**References**


International Archives of Otorhinolaryngology Vol. 26 No. 1/2022 © 2021. Fundação Otorrinolaringologia. All rights reserved.
The Application of P300-Long-Latency Auditory-Evoked Potential in Parkinson Disease


Mello MPB, Botelho ACG. Correlation of evaluation scales utilized at Parkinson’s disease applied to physical therapy. Fisioter Mov 2010;23:121–127.


Peavy GM. Mild cognitive deficits in Parkinson’s disease: where there is bradykinesia, there is bradypnea. Neurology 2010;75(12):1038–1039.


Chaudhuri A, Behan PO. Fatigue and basal ganglia. J Neurol Sci 2000;179((S 1-2)):34–42.


